This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barry, A. L.
Right arrow Articles by Brown, S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barry, A. L.
Right arrow Articles by Brown, S. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2001, p. 2922-2924, Vol. 45, No. 10
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.10.2922-2924.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

In Vitro Activity of the Ketolide ABT-773

Arthur L. Barry,* Peter C. Fuchs, and Steven D. Brown

The Clinical Microbiology Institute, Wilsonville, Oregon 97070

Received 19 March 2001/Returned for modification 5 June 2001/Accepted 3 July 2001

The in vitro activities of ABT-773, azithromycin, erythromycin, and clindamycin were compared by testing 1,223 clinical isolates selected to represent different species and phenotypes. ABT-773 was particularly potent against staphylococci (the MIC at which 90% of the strains tested were inhibited [MIC90] was <= 0.06 µg/ml), including all strains that were macrolide resistant but clindamycin susceptible. Streptococcus pneumoniae and other streptococci were inhibited by low concentrations of ABT-773, and that included most erythromycin-resistant strains. Against Haemophilus influenzae, ABT-773 and azithromycin were similar in their antibacterial potency (MIC90, 4.0 and 2.0 µg/ml, respectively).

* Corresponding author. Mailing address: 9725 S.W. Commerce Circle, Suite A1, Wilsonville, OR 97070. Phone: (503) 682-3232. Fax: (503) 682-4548. E-mail: cmi{at}hevanet.com.

Antimicrobial Agents and Chemotherapy, October 2001, p. 2922-2924, Vol. 45, No. 10
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.10.2922-2924.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Rios, A. M., Mejias, A., Chavez-Bueno, S., Fonseca-Aten, M., Katz, K., Hatfield, J., Gomez, A. M., Jafri, H. S., McCracken, G. H. Jr., Ramilo, O., Hardy, R. D. (2004). Impact of Cethromycin (ABT-773) Therapy on Microbiological, Histologic, Immunologic, and Respiratory Indices in a Murine Model of Mycoplasma pneumoniae Lower Respiratory Infection. Antimicrob. Agents Chemother. 48: 2897-2904 [Abstract] [Full Text]  
  • Reinert, R. R. (2004). Clinical efficacy of ketolides in the treatment of respiratory tract infections. J Antimicrob Chemother 53: 918-927 [Abstract] [Full Text]  
  • Hamilton-Miller, J. M. T., Shah, S. (2002). Activity of ketolide ABT-773 (cethromycin) against erythromycin-resistant Streptococcus pneumoniae: correlation with extended MLSK phenotypes. J Antimicrob Chemother 50: 907-913 [Abstract] [Full Text]  
  • Schmitz, F.-J., Schwarz, S., Milatovic, D., Verhoef, J., Fluit, A. C. (2002). In vitro activities of the ketolides ABT-773 and telithromycin and of three macrolides against genetically characterized isolates of Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis. J Antimicrob Chemother 50: 145-148 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»